Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies

Authors

Beth Schwartz, Henry Ford HealthFollow
Katherine Klamer, Henry Ford HealthFollow
Justin Zimmerman, Henry Ford Health
Pramodini B. Kale-Pradhan, Henry Ford HealthFollow
Ashish Bhargava, Henry Ford HealthFollow

Recommended Citation

Schwartz B, Klamer K, Zimmerman J, Kale-Pradhan PB, and Bhargava A. Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies. Pathogens 2024; 13(11).

Document Type

Article

Publication Date

11-7-2024

Publication Title

Pathogens

Abstract

Pseudomonas aeruginosa is causing increasing concern among clinicians due to its high mortality and resistance rates. This bacterium is responsible for various infections, especially in hospital settings, affecting some of the most vulnerable patients. Pseudomonas aeruginosa has developed resistance through multiple mechanisms, making treatment challenging. Diagnostic techniques are evolving, with rapid testing systems providing results within 4-6 h. New antimicrobial agents are continuously being developed, offering potential solutions to these complex clinical decisions. This article provides a review of the epidemiology, at-risk populations, resistance mechanisms, and diagnostic and treatment options for Pseudomonas aeruginosa.

PubMed ID

39599528

Volume

13

Issue

11